Kazuo Ueda’s speech did not mention consecutive interest rate hikes at all; Is the Bank of Japan set to hold rates unchanged in October?
Bank of Japan Governor Kazuo Ueda has shown little intention of challenging the market's current bearish bets on the central bank delivering a second consecutive rate hike this month.
Zhihu Finance APP noted that Bank of Japan Governor Kazuo Ueda showed virtually no intention of challenging the market’s current bearish bets on a second consecutive rate hike by the central bank this month, merely reiterating the bank’s consistent policy stance.
During a brief speech in Tokyo on Tuesday, Kazuo Ueda stated, “We intend to continue raising policy rates and adjust the degree of monetary easing depending on changes in economic activity, prices, and financial conditions.”
The central bank governor said, “We will consider the timing and pace of these adjustments as we assess risks and the likelihood of the baseline outlook for the economy and prices being realized.”
These remarks come at a time when economists generally expect the Bank of Japan to keep policy unchanged at the next monetary policy committee meeting on October 30. By reiterating the central bank’s policy stance and economic perspective, Kazuo Ueda did little to dispel these expectations while leaving room for rate hikes after October.
Pricing of overnight index swaps indicates that investors see about a 12% probability of a rate hike this month, down from as high as 40% earlier last week. If the December meeting is taken into account, the probability of a rate hike rises sharply to around 90%.
The governor reiterated views he expressed after last month’s policy rate hike, emphasizing the need to prevent inflation from overshooting the target.
Kazuo Ueda stated, “We believe it is becoming increasingly important to stabilize the underlying inflation rate around 2%, and to ensure that the risk of inflation exceeding the 2% price stability target does not materialize and adversely affect the economy.”
The Bank of Japan raised its benchmark interest rate on September 18, just three months after the June rate hike, marking the shortest interval between hikes since 1990. In the press conference following the meeting, Kazuo Ueda said the bank’s policy phase had shifted to focusing on stabilizing price trends, rather than advancing them toward the 2% target as in the past 13 years.
Kazuo Ueda stated that it is necessary to pay close attention to risks arising from the Middle East conflict, demand related to artificial intelligence, and exchange rate fluctuations. He added that there is a possibility that underlying inflation could rise above the target.
In the summary of opinions from the September meeting, a government official—likely Minister of State for Economic and Fiscal Policy Yoshimasa Hayashi—stated that the government hopes the Bank of Japan will carefully assess the impact of interest rate hikes implemented so far, indicating a cautious attitude toward further rate increases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-BridgeBio shares rise as FDA initiates priority review for dwarfism drug
On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)
Google (GOOGL.US) spends $4.3 billions on electricity, securing 3,590 megawatts of long-term energy from Constellation Energy (CEG.US).
Google has signed a 3,590 MW power purchase agreement with Constellation Energy, with a quarter of the electricity coming from nuclear power, involving an investment of $4.3 billion.
BUZZ - Torm shares decline as Oaktree exits in a $253.5 million secondary offering
Updated Pricing Details: On October 6th, before the market opened on Tuesday, shares of the tanker operator Torm (TRMD.O), listed in the US, dropped 3.2% to $39.72 after the company announced the pricing of its secondary offering. According to the company (link), funds managed by Oaktree Capital Management sold approximately 6.3 million shares, raising a total of about $253.5 million. The secondary offering was priced at $40.05 per share, a 2.4% discount to the stock's previous closing price. According to the prospectus, Oaktree Capital completely exited its remaining approximately 6.2% stake following the sale (link). JPMorgan served as the sole underwriter for this issuance. Last month, Oaktree Capital (link) sold shares in another secondary offering of 9 million shares at $32.25 per share. Driven by record freight rates, the shares of tankers listed in Northern Europe (link) have soared, and Torm's stock closed up 2.6% on Monday at $41.05. As of Monday’s close, the company’s US-listed shares had surged about 110% year-to-date, including a 47% gain over the past three months. (For the convenience of non-English speakers, Reuters provides its report with automated translation into several languages. Due to the possibility of errors or the lack of contextual accuracy from automated translation, Reuters does not guarantee the accuracy of these texts. The automated translation is provided for readers’ convenience only. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)
BRIEF-Lamb Weston Holdings Announces Quarterly Dividend
Lamb Weston Holdings, Inc. LW.N: LAMB WESTON HOLDINGS ANNOUNCES QUARTERLY DIVIDEND LAMB WESTON HOLDINGS - DECLARES QTRLY DIVIDEND OF $0.38 PER SHARE Source text: ID:nBwWVH9na Further company coverage: LW.N
Crypto prices
More
